doi: 10.1016/j.fsi.2019.07.056 213 NiuK
Patient Eligibility Before starting treatment, patients must complete a medical consultation, share their medical history, discuss any current medications, and undergo initial blood tests
Gilead Chairman and CEO Daniel ODay called Livdelzi an important new option for patients and doctors, adding, People living with PBC [primary biliary cholangitis] have been waiting for treatment advancements for many years. Livdelzis approval is supported by the Phase III RESPONSE trial, in which treatment with the drug elicited a significantly higher rate of composite biochemical response
Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons